Form 8-K - Current report:
SEC Accession No. 0001193125-24-075991
Filing Date
2024-03-25
Accepted
2024-03-25 08:54:55
Documents
16
Period of Report
2024-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d779916d8k.htm   iXBRL 8-K 53732
2 EX-2.1 d779916dex21.htm EX-2.1 671473
3 EX-10.1 d779916dex101.htm EX-10.1 37249
4 EX-99.1 d779916dex991.htm EX-99.1 19484
  Complete submission text file 0001193125-24-075991.txt   1096950

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA labp-20240324.xsd EX-101.SCH 2862
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20240324_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20240324_pre.xml EX-101.PRE 11266
19 EXTRACTED XBRL INSTANCE DOCUMENT d779916d8k_htm.xml XML 3625
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

EIN.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 24777017
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)